Journal of Clinical InvestigationImmunologyPeer-reviewed journal article
Reverse genetics in humanized mice reveals CARD8-mediated pyroptosis causing pancytopenia in human DPP9 deficiency
Tianli XiaoiD, J. Richard Brewer, Maximillian J. CarlinoiD, Ailin Han, Yamato J. TakabeiD, Chia‐Yi LeeiD, Fengrui ZhangiD, Mi Chen, Holly N. BlackburniD, Amin H. NassariD, Qiankun WangiD, Kristen BrennandiD, Liang ShaniD, Esen SefikiD, Diane S. KrauseiD, Richard Anthony FlavelliD
Abstract
Loss of function mutation in the human DPP9 gene causes Hatipoglu syndrome leading to severe inflammasomopathy. A key feature of the disease is pancytopenia and patients require bone marrow transplantation, but the mechanism of cell loss is unclear since Dpp9 mutant mice have normal hematopoiesis, suggesting that a distinct mechanism of disease occurs in humans. Here, we present a model of human DPP9 deficiency leveraging reverse genetics in the MISTRG6 humanized mice. We found that CRISPR editing of human CD34+ hematopoietic stem and progenitor cells (HSPCs) led to very efficient and persistent gene deletion in vivo. Human DPP9 deletion recapitulated cytopenia in peripheral blood and in the bone marrow, and cell loss was cell intrinsic. However, DPP9 deletion led to little transcriptional changes suggesting post-transcriptional regulation in human HSPCs. Mechanistically, DPP9 deficiency led to the activation of the CARD8 inflammasome resulting in HSPC pyroptosis, whereas NLRP1 was dispensable for cell death. Thus, our results reveal a unique human mechanism of disease and offer therapeutic insight for this inflammasomopathy.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: cell signaling & trafficking
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: experimental assay
- approach: wet-lab / biochemical assay
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- top 39%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- DPP9 deficiency: an inflammasomopathy which can be rescued by lowering NLRP1/IL-1 signaling
Cassandra R. Harapas, Kim S. Robinson, … Bruno Reversade·Science ImmunologyPeer-reviewed·Sep 16, 2022
- RUNX1 haploinsufficiency causes a marked deficiency of megakaryocyte-biased hematopoietic progenitor cells: Mechanistic studies and drug correction
Brian Estevez, Sara Borst, … Mortimer Poncz·bioRxiv·Aug 23, 2020
- Clinically Relevant Gene Editing in Hematopoietic Stem Cells for the Treatment of Pyruvate Kinase Deficiency Hemolytic Anemia
Sara Fañanas-Baquero, Oscar Quintana Bustamante, … Jose Carlos Segovia·Molecular Therapy — Methods & Clinical DevelopmentPeer-reviewed·May 13, 2021
- Immune regeneration in irradiated mice is not impaired by the absence of DPP9 enzymatic activity
M. G. Gall, H. E. Zhang, … M. D. Gorrell·bioRxiv·Oct 1, 2018
- DPP9 is an endogenous and direct inhibitor of the NLRP1 inflammasome that guards against human auto-inflammatory diseases
Franklin L. Zhong, Kim Robinson, … Bruno Reversade·bioRxiv·Feb 7, 2018
- Humanized mice bearing CRISPR/Cas9 Disruption of Signal Transducer and Activator of Transcription 1 (STAT1) to Model Primary Immunodeficiency
J. L. Aron, T. J. Thauland, … M. J. Butte·bioRxiv·Jun 20, 2022